The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy

[1] Ho GY(2016)Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies Crit Rev Oncol Hematol 102 37-46

[2] Woodward N(2017)Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis Clin Genitourin Cancer 15 23-30.e2

[3] Coward JI(2013)Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer Hinyokika Kiyo 59 1-6

[4] Necchi A(2011)Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study Cancer 117 5500-5508

[5] Pond GR(2012)Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review BJU Int 110 1426-1435

[6] Raggi D(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[7] Sumiyoshi T(2007)The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging BJU Int 99 973-977

[8] Matsumoto K(2015)The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy Urol Oncol 33 495.e9-495.e14

[9] Utsunomiya N(2016)Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience Jpn J Clin Oncol 46 163-169

[10] Segawa T(2013)The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma J Cancer 4 686-690

[1] Ho GY(2016)Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies Crit Rev Oncol Hematol 102 37-46

[2] Woodward N(2017)Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis Clin Genitourin Cancer 15 23-30.e2

[3] Coward JI(2013)Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer Hinyokika Kiyo 59 1-6

[4] Necchi A(2011)Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study Cancer 117 5500-5508

[5] Pond GR(2012)Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review BJU Int 110 1426-1435

[6] Raggi D(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[7] Sumiyoshi T(2007)The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging BJU Int 99 973-977

[8] Matsumoto K(2015)The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy Urol Oncol 33 495.e9-495.e14

[9] Utsunomiya N(2016)Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience Jpn J Clin Oncol 46 163-169

[10] Segawa T(2013)The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma J Cancer 4 686-690